Skip to content
Samrat Pharmachem logo

Samrat Pharmachem

530125 BSE
Price unavailable

Samrat Pharmachem (SAMRATPH) share price was ₹266.00 at the 28 Oct 2026 close; market capitalisation ₹82.20 Cr; sector Healthcare. The share price fell 4.0% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 5.4% year on year to ₹79.76 Cr and net profit was ₹0.88 Cr, against −₹0.23 Cr a year earlier (compared with Jun 2025). Promoters held 49.09% of Samrat Pharmachem in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 58/100 (Good) as of 28 Oct 2026.

Close 28 Oct 2026 ₹266.00 −30.70 −10.35% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹82.20 Cr
EBITDA
−₹1.30 Cr
Return on Equity
-4.86%
Debt to Equity
0.16
Book Value
₹220.67
EPS (TTM)
−₹7.15
52W High
₹309.85
52W Low
₹190.00

Price-based figures as of 28 Oct 2026, 15:30 IST · EPS basis: Standalone · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,767.6035.064,24,106 Cr5.070.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,659.0087.672,56,416 Cr15.300.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,609.6072.361,75,334 Cr9.540.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,187.10108.061,18,172 Cr22.300.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,181.0026.281,17,805 Cr4.350.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,338.4034.661,11,714 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,362.2032.641,10,046 Cr3.110.96%11.21%14.88%28,589 Cr3,356 Cr
Samrat Pharmachem (this company)
——82 Cr1.210.37%-4.86%-2.95%295 Cr-2 Cr
Median 8 companies₹1,767.6035.061,17,988 Cr4.710.49%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

58 Good
Overall score

Data confidence 91/100

Category scores

Quality Good 60
Returns, margins, earnings quality 22% weight
Valuation Strong 69
Cheap vs sector & own history 24% weight
Growth Weak 44
Sales & profit trajectory 9% weight
Financial Health Poor 37
Solvency, leverage, coverage 9% weight
Momentum Strong 87
Trend strength, vol-adjusted 12% weight
Ownership Average 50
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Stock is trading at 1.09 times its book value

Weaknesses

3
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 10.1% over past five years.
  • Company has a low return on equity of 2.15% over last 3 years.

Technical Indicators

Oscillators

Bullish

Bearish
0
Neutral
6
Bullish
3

Overall

Bullish

Bearish
0
Neutral
6
Bullish
13

Moving Averages

Bullish

Bearish
0
Neutral
0
Bullish
10

Growth Rate

Revenue Growth
1.32% higher than 3Y

change over 1 year

Net Income Growth
-146% higher than 3Y

change over 1 year

Cash Flow Change
188%

change over 1 year

EBITDA Margin Change
-112%

change over 1 year Operating margin 1.12% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
57.48
79.74
61.67
82.68
80.82
70.17
63.66
71.2
75.65
78.87
63.43
71.77
79.76
Expenses
56.71
79.51
61.56
81.32
78.24
66.8
59.48
71.07
75.52
79.23
64.08
73.01
78.87
Operating Profit
0.77
0.23
0.11
1.36
2.58
3.37
4.18
0.13
0.13
-0.36
-0.65
-1.24
0.89
OPM %
1.34%
0.29%
0.18%
1.64%
3.19%
4.8%
6.57%
0.18%
0.17%
-0.46%
-1.02%
-1.73%
1.12%
Other Income
0.36
0.3
0.42
0.3
0.59
0.49
0
-0.11
0.69
0.05
0.4
-0.31
0.99
Interest
0.22
0.13
0.23
0.11
0.19
0.17
0.1
0.22
0.44
0.26
0.13
0.14
0.11
Depreciation
0.16
0.16
0.16
0.16
0.16
0.17
0.17
0.16
0.17
0.18
0.19
0.19
0.19
PBT
0.75
0.24
0.14
1.39
2.82
3.52
3.91
-0.36
0.21
-0.75
-0.57
-1.88
1.58
Tax %
18.67%
175%
-142.86%
0%
26.6%
24.43%
28.9%
11.11%
209.52%
-21.33%
-19.3%
8.51%
44.94%
Net Profit
0.61
-0.19
0.34
1.4
2.07
2.66
2.78
-0.4
-0.23
-0.59
-0.46
-2.04
0.88
EPS (₹)
1.97
-0.61
1.1
4.53
6.7
8.61
9
-1.29
-0.74
-1.91
-1.49
-6.6
2.85
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
47
63
73
93
111
137
179
222
311
282
286
290
294
Expenses
46
62
69
87
108
131
170
197
287
279
276
292
295
Operating Profit
1
1
4
6
3
7
9
24
24
2
10
-2
-1
OPM %
2.5%
1.9%
5%
6%
2.9%
4.8%
4.8%
11%
8%
0.9%
3.6%
-0.7%
-0.5%
Other Income
0
0
0
0
0
1
0
1
0
1
1
1
1
Interest
1
1
1
1
1
1
1
1
1
1
1
1
1
Depreciation
0
0
0
0
0
0
0
1
1
1
1
1
1
PBT
0
0
3
5
2
6
7
24
23
3
10
-3
-2
Tax %
35%
33%
37%
35%
29%
27%
27%
27%
26%
14%
28%
11%
—
Net Profit
0
0
2
3
2
4
5
17
17
2
7
-3
-2
EPS (₹)
1.04
0.97
5.66
10.42
4.98
13.72
17.25
55.6
53.82
6.99
23.01
-10.71
-7.15
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
2%
2%
14%
4%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
3
3
3
3
3
3
3
3
3
3
3
3
Reserves
10
11
12
15
17
21
27
44
60
62
69
65
Borrowings
3
6
7
9
7
9
9
8
19
8
10
11
Other Liabilities
10
17
14
13
14
25
19
30
35
48
40
46
Total Liabilities
26
36
36
41
40
58
57
85
117
122
122
124
Fixed Assets
7
7
7
7
7
7
9
10
11
11
10
12
CWIP
0
0
0
0
0
1
0
0
0
0
0
1
Investments
0
2
0
0
0
0
0
0
2
3
4
4
Other Assets
19
27
29
34
33
50
48
75
104
108
107
108
Total Assets
26
36
36
41
40
58
57
85
117
122
122
124
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
-1
0
-3
0
2
-1
5
17
-9
9
-10
9
Investing
0
-2
1
-2
2
-2
-3
-1
-3
0
0
-3
Financing
0
2
1
2
-4
2
-2
-2
10
-11
0
0
Net Cash Flow
0
0
-1
-1
1
-1
0
14
-3
-2
-10
6
Free Cash Flow
-1
-1
-4
0
2
-3
3
16
-11
9
-11
6
CFO/OP
-29
-25
-73
17
126
-7
81
78
0
503
-84
-493
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
74
93
59
86
69
74
67
72
61
90
72
64
Inventory Days
38
37
41
31
28
55
25
24
43
28
52
56
Days Payable
76
104
43
46
45
67
39
45
42
65
53
55
Cash Conversion Cycle
36
26
58
70
52
61
53
51
62
53
71
65
Working Capital Days
19
14
34
32
37
39
36
32
40
47
68
52
ROCE %
7%
5%
16%
23%
12%
22%
24%
52%
35%
3%
13%
-3%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Samrat Pharmachem insights

68 extracted metrics + investor summaries across FY11–FY27.

Shareholding Pattern

FIIs3.24%Promot.49.09%Others5.88%Public41.79%As ofSep 2026

Documents

Frequently Asked Questions about Samrat Pharmachem

What does Samrat Pharmachem Ltd do?
Incorporated in 1992, Samrat Pharmachem Ltd does manufacturing and selling of chemicals[1]
Where is Samrat Pharmachem Ltd (SAMRATPH) listed?
Samrat Pharmachem Ltd trades under code 530125 on the BSE.
Which sector does Samrat Pharmachem Ltd belong to?
Samrat Pharmachem Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Samrat Pharmachem Ltd?
Samrat Pharmachem Ltd has a market capitalisation of ₹82.2 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the 52-week high and low of Samrat Pharmachem Ltd?
Over the last 52 weeks Samrat Pharmachem Ltd has traded between ₹190 and ₹309.85 as of 28 Oct 2026.
Does Samrat Pharmachem Ltd pay dividends?
Samrat Pharmachem Ltd has a dividend yield of 0.38%.
What is the Return on Equity (ROE) of Samrat Pharmachem Ltd?
Samrat Pharmachem Ltd reported a return on equity of -4.86%. Its debt-to-equity ratio is 0.16.

Company Information

Incorporated in 1992, Samrat Pharmachem Ltd does manufacturing and selling of chemicals[1]

Website samratpharmachem.com
Face Value ₹ 10
Shares Outstanding 30,90,208

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/530125.md for Samrat Pharmachem Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month